---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-005357"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:34:03.329128+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# COMPASS Pathways reports FY2022 net loss of $91.5M; Phase 3 psilocybin trials underway

## Summary
- Net loss for FY2022 was $91.5M ($2.16 loss per share) vs $71.7M ($1.79 loss per share) in 2021.
- Cash and cash equivalents fell to $143.2M at Dec 31, 2022 from $273.2M a year earlier.
- Phase 3 pivotal program for COMP360 psilocybin in TRD ongoing; top-line data from trial COMP 005 expected summer 2024.
- R&D expenses increased to $65.1M in FY2022 from $44.0M in FY2021, driven by clinical development.
- FY2023 net cash used in operating activities guided at $85M-$110M; Q1 2023 at $24M-$32M.

## SEC filing metadata
- accession: 0001628280-23-005357
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000162828023005357/0001628280-23-005357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000162828023005357/cmps-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-005357
- JSON: https://secwatch.observer/filing/0001628280-23-005357.json
- Plain text: https://secwatch.observer/filing/0001628280-23-005357.txt

## Key facts
- Earnings Releases
  COMPASS Pathways plc reported the three months ended December 31, 2022 results: net income $30.9 million, EPS $0.73 loss per share.
  - Period: the three months ended December 31, 2022
  - Net income: $30.9 million
  - EPS: $0.73 loss per share
  - Result: reported results
  source text: Net loss for the three months ended 31 December 2022 was $30.9 million, or $0.73 loss per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816590/000162828023005357/0001628280-23-005357-index.htm
- Earnings Releases
  COMPASS Pathways plc reported the year ended December 31, 2022 results: net income $91.5 million, EPS $2.16 loss per share.
  - Period: the year ended December 31, 2022
  - Net income: $91.5 million
  - EPS: $2.16 loss per share
  - Result: reported results
  source text: Net loss for the year ended 31 December 2022 was $91.5 million, or $2.16 loss per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816590/000162828023005357/0001628280-23-005357-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.